EXE, IP, ESPR, CMPS, TNXP Trending With Analysts

Analysts are intrested in these 5 stocks: ( (EXE) ), ( (IP) ), ( (ESPR) ), ( (CMPS) ) and ( (TNXP) ). Here is a breakdown of their recent ratings and the rationale behind them.

Expand Energy’s latest results have impressed analysts, but not enough to keep its previous bullish ratings intact. Neal Dingmann downgraded EXE to Hold, even as he highlighted a strong first-quarter earnings beat, higher free cash flow, and disciplined capital spending tied partly to timing.

The firm reaffirmed 2026 guidance and is targeting roughly $500 million in extra free cash flow plus a notable efficiency gain per unit of production. Dingmann points to long-term LNG offtake deals, such as with Delfin FLNG 1, and potential midstream opportunities as key drivers, suggesting the story is solid but now fairly reflected in the stock.

International Paper is back in favor with Wall Street as Mark Weintraub at Seaport upgrades IP to Buy with a $39 target. He sees a classic turnaround setup under CEO Andy Silvernail, with tough restructuring moves and a long list of projects that could boost earnings power over the next few years.

Weintraub also notes a powerful industry tailwind from significant containerboard capacity cuts since 2025, which should support pricing for IP’s North American business. With the stock halved from about $60 to around $30 and trading at modest EV/EBITDA multiples, he argues IP does not need to hit its original lofty goals for shareholders to see upside, despite ongoing transition and de‑merger risks.

Esperion’s story has shifted from growth to exit as two analysts move to the sidelines following its take‑private deal. Joseph Pantginis downgraded ESPR to Hold with a $3.16 target, matching the all‑cash offer price from healthcare investor ARCHIMED, plus non‑tradeable contingent value rights tied to future drug sales.

Pantginis highlights that the acquisition values Esperion at up to $1.1 billion if sales milestones are met, reflecting confidence in its expanding cardiometabolic franchise, including the BDA and ENBUMYST products and a pipeline stretching into the next decade. With the stock price essentially locked to the deal and risks now more about transaction completion than operations, he sees limited upside for public investors.

A similar view comes from Serge Belanger, who also downgraded Esperion to Hold after the ARCHIMED bid. He stresses that the 58% premium to the prior close and additional CVR milestones make a rival offer unlikely, suggesting the sale process has effectively run its course.

Belanger notes the transaction is expected to close in the third quarter of 2026, subject to standard conditions. For investors, ESPR now trades more like a merger‑arbitrage situation than a traditional biotech growth play, with return potential capped by the agreed buyout terms.

COMPASS Pathways is attracting fresh attention as Andrew Tsai kicks off coverage of CMPS with a Buy rating and an $18 price target. He argues there is a high probability that COMP360, an oral psilocybin therapy, wins FDA approval for treatment‑resistant depression by the end of 2026, targeting a multibillion‑dollar market.

Tsai points to robust Phase IIb and Phase III data, FDA breakthrough designation, and a favorable backdrop created by J&J’s Spravato, which has already prepared clinics and payors for novel, clinic‑based depression therapies. With COMP360 offering potentially more durable relief on far fewer doses and leveraging existing infrastructure, he believes the stock could climb sharply on approval and a successful launch.

Tonix Pharmaceuticals is emerging as a speculative growth story in pain and central nervous system disorders, with Stacy Ku initiating coverage of TNXP at Buy and a $22 price target. Her bullish thesis centers on Tonmya, an FDA‑approved sublingual cyclobenzaprine tablet for fibromyalgia, where early real‑world use shows encouraging improvements in pain and sleep.

Ku notes that Tonix is targeting a concentrated group of high‑prescribing clinicians and already seeing promising adoption trends, with thousands of patients started on therapy and sales ramping from launch. With a large population of fibromyalgia patients poorly served by existing drugs and a potential peak sales opportunity above $600 million, plus upside from Lyme disease candidate TNX‑4800, she sees Tonix as a compelling early‑stage growth name.